Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia

J. Ochs, J. A. Sinkule, M. K. Danks, A. T. Look, Paul Bowman, G. Rivera

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Ten pediatric patients with refractory leukemia received continuous infusion high-dose cytosine arabinoside (ara-C) according to one of two escalating dosage schedules: (1) a 500-mg/m2 rapid infusion loading dose followed by 3.5 g/m2 per day continuous infusion daily for four days, or (2) a 600-mg/m2 rapid infusion loading dose followed by 5.0 g/m2 per day continuous infusion daily for four consecutive days. Major toxicity at the lower dosage level was grade IV hematopoietic aplasia of three weeks' duration. At the higher dosage level, there was a prohibitive toxicity in multiple organ systems including transient noncardiogenic pulmonary edema, fungal infections, peritonitis, severe diarrhea, transaminase elevations, and one treatment-related death due to acute renal failure. In contrast to other methods of administration of high-dose ara-C, no CNS toxicity occurred. Oncolytic responses were seen in all patients and two achieved brief, partial remissions. Steady-state plasma ara-C concentrations were 13 to 40 μmol/L at the 3.5-g/m2 dosage level and 10 to 225 μmol/L at the 5-g/m2 dosage level; CSF concentrations at both dosages ranged from 2 to 5 μmol/L. Intracellular levels and ratios of 1-β-D-arabinofuranosylcytidine-5'triphosphate and endogenous deoxycytidine 5'-triphosphate in marrow blasts varied widely at steady state infusion. No positive correlation existed between steady-state plasma ara-C levels, toxicity, oncolytic effect, or intracellular nucleotide concentration.

Original languageEnglish
Pages (from-to)1092-1097
Number of pages6
JournalJournal of Clinical Oncology
Volume2
Issue number10
DOIs
StatePublished - 1 Jan 1984

Fingerprint

Cytarabine
Leukemia
Fungal Lung Diseases
Pulmonary Edema
Transaminases
Peritonitis
Acute Kidney Injury
Diarrhea
Appointments and Schedules
Nucleotides
Bone Marrow
Pediatrics

Cite this

Ochs, J. ; Sinkule, J. A. ; Danks, M. K. ; Look, A. T. ; Bowman, Paul ; Rivera, G. / Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. In: Journal of Clinical Oncology. 1984 ; Vol. 2, No. 10. pp. 1092-1097.
@article{595b25929fb54def8b38650a348f7409,
title = "Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia",
abstract = "Ten pediatric patients with refractory leukemia received continuous infusion high-dose cytosine arabinoside (ara-C) according to one of two escalating dosage schedules: (1) a 500-mg/m2 rapid infusion loading dose followed by 3.5 g/m2 per day continuous infusion daily for four days, or (2) a 600-mg/m2 rapid infusion loading dose followed by 5.0 g/m2 per day continuous infusion daily for four consecutive days. Major toxicity at the lower dosage level was grade IV hematopoietic aplasia of three weeks' duration. At the higher dosage level, there was a prohibitive toxicity in multiple organ systems including transient noncardiogenic pulmonary edema, fungal infections, peritonitis, severe diarrhea, transaminase elevations, and one treatment-related death due to acute renal failure. In contrast to other methods of administration of high-dose ara-C, no CNS toxicity occurred. Oncolytic responses were seen in all patients and two achieved brief, partial remissions. Steady-state plasma ara-C concentrations were 13 to 40 μmol/L at the 3.5-g/m2 dosage level and 10 to 225 μmol/L at the 5-g/m2 dosage level; CSF concentrations at both dosages ranged from 2 to 5 μmol/L. Intracellular levels and ratios of 1-β-D-arabinofuranosylcytidine-5'triphosphate and endogenous deoxycytidine 5'-triphosphate in marrow blasts varied widely at steady state infusion. No positive correlation existed between steady-state plasma ara-C levels, toxicity, oncolytic effect, or intracellular nucleotide concentration.",
author = "J. Ochs and Sinkule, {J. A.} and Danks, {M. K.} and Look, {A. T.} and Paul Bowman and G. Rivera",
year = "1984",
month = "1",
day = "1",
doi = "10.1200/JCO.1984.2.10.1092",
language = "English",
volume = "2",
pages = "1092--1097",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. / Ochs, J.; Sinkule, J. A.; Danks, M. K.; Look, A. T.; Bowman, Paul; Rivera, G.

In: Journal of Clinical Oncology, Vol. 2, No. 10, 01.01.1984, p. 1092-1097.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia

AU - Ochs, J.

AU - Sinkule, J. A.

AU - Danks, M. K.

AU - Look, A. T.

AU - Bowman, Paul

AU - Rivera, G.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Ten pediatric patients with refractory leukemia received continuous infusion high-dose cytosine arabinoside (ara-C) according to one of two escalating dosage schedules: (1) a 500-mg/m2 rapid infusion loading dose followed by 3.5 g/m2 per day continuous infusion daily for four days, or (2) a 600-mg/m2 rapid infusion loading dose followed by 5.0 g/m2 per day continuous infusion daily for four consecutive days. Major toxicity at the lower dosage level was grade IV hematopoietic aplasia of three weeks' duration. At the higher dosage level, there was a prohibitive toxicity in multiple organ systems including transient noncardiogenic pulmonary edema, fungal infections, peritonitis, severe diarrhea, transaminase elevations, and one treatment-related death due to acute renal failure. In contrast to other methods of administration of high-dose ara-C, no CNS toxicity occurred. Oncolytic responses were seen in all patients and two achieved brief, partial remissions. Steady-state plasma ara-C concentrations were 13 to 40 μmol/L at the 3.5-g/m2 dosage level and 10 to 225 μmol/L at the 5-g/m2 dosage level; CSF concentrations at both dosages ranged from 2 to 5 μmol/L. Intracellular levels and ratios of 1-β-D-arabinofuranosylcytidine-5'triphosphate and endogenous deoxycytidine 5'-triphosphate in marrow blasts varied widely at steady state infusion. No positive correlation existed between steady-state plasma ara-C levels, toxicity, oncolytic effect, or intracellular nucleotide concentration.

AB - Ten pediatric patients with refractory leukemia received continuous infusion high-dose cytosine arabinoside (ara-C) according to one of two escalating dosage schedules: (1) a 500-mg/m2 rapid infusion loading dose followed by 3.5 g/m2 per day continuous infusion daily for four days, or (2) a 600-mg/m2 rapid infusion loading dose followed by 5.0 g/m2 per day continuous infusion daily for four consecutive days. Major toxicity at the lower dosage level was grade IV hematopoietic aplasia of three weeks' duration. At the higher dosage level, there was a prohibitive toxicity in multiple organ systems including transient noncardiogenic pulmonary edema, fungal infections, peritonitis, severe diarrhea, transaminase elevations, and one treatment-related death due to acute renal failure. In contrast to other methods of administration of high-dose ara-C, no CNS toxicity occurred. Oncolytic responses were seen in all patients and two achieved brief, partial remissions. Steady-state plasma ara-C concentrations were 13 to 40 μmol/L at the 3.5-g/m2 dosage level and 10 to 225 μmol/L at the 5-g/m2 dosage level; CSF concentrations at both dosages ranged from 2 to 5 μmol/L. Intracellular levels and ratios of 1-β-D-arabinofuranosylcytidine-5'triphosphate and endogenous deoxycytidine 5'-triphosphate in marrow blasts varied widely at steady state infusion. No positive correlation existed between steady-state plasma ara-C levels, toxicity, oncolytic effect, or intracellular nucleotide concentration.

UR - http://www.scopus.com/inward/record.url?scp=0021193821&partnerID=8YFLogxK

U2 - 10.1200/JCO.1984.2.10.1092

DO - 10.1200/JCO.1984.2.10.1092

M3 - Article

C2 - 6593435

AN - SCOPUS:0021193821

VL - 2

SP - 1092

EP - 1097

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -